Direct Spraying of MINCLEA on the Duodenal Papilla for Preventing Post-ERCP Pancreatitis

Direct Spraying of MINCLEA on the Duodenal Papilla for Preventing Post-ERCP Pancreatitis - Direct Spraying of MINCLEA on the Duodenal Papilla for Preventing Post-ERCP Pancreatitis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013086

Enrollment

Registered

2014-02-06

Start date

2014-02-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

post-ERCP pancreatitis

Interventions

MINCLEA group sprays MINCLEA on duodenal papilla directly after ERCP. Placebo group sprays physiological saline on duodenal papilla directly after ERCP.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who are planned to perform ERCP for further evaluation or treatment. 2) Written informed consent is obtained from patient before the study.

Exclusion criteria

Exclusion criteria: 1) Patients with hypersensitivity to MINCLEA. 2) Patients with a history of EST and EPBD. 3) Patients with receiving endoscopic therapy of ENBD, ENPD, biliary stent or pancreatic stent. 4) Patients with acute pancreatitis. 5) Patients with chronic pancreatitis. 6) Patients with divism or pancreaticobiliary maljunction 7) Patients who are judged inappropriate by chief (responsive) medical examiner.

Design outcomes

Primary

Measure	Time frame
Incidence rate of post-ERCP pancreatitis	—

Countries

Japan

Contacts

Public ContactYuta Koike

Sapporo City General Hospital Department of Gastroenterology

yutakoike1217@gmail.com011-726-2211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026